

EARLY WARNING REPORT

Pursuant to National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues

- (a) *Name and Address of the offeror.*

Rob Hutchison
4 - 3300 157A Street
Surrey, BC V3S 2P2

- (b) *The designation and number or principal amount of securities and the offeror's securityholding percentage in the class of securities of which the offeror acquired ownership or control in the transaction or occurrence giving rise to the obligation to file the news release, and whether it was ownership or control that was acquired in those circumstances.*

Mr. Rob Hutchison (the "**Offeror**") has acquired direct ownership of 1,325,000 common shares of bioMmune Technologies Inc. (formerly MC Partners Inc.) (the "**Issuer**") and control and direction over an additional 1,325,000 common shares of the Issuer (collectively the "**Shares**"), representing collectively approximately 11.73% of the Issuer's issued and outstanding common shares.

The Shares were acquired pursuant to the terms of the share exchange agreement dated for reference April 22, 2013 between the Issuer, bioMmune Advanced Technologies Inc. (formerly bioMmune Technologies Inc. and now a wholly-owned subsidiary of the Issuer) ("**BAT**") and BAT shareholders (the "**Shares Exchange Agreement**"), whereby the Issuer acquired all of the issued and outstanding shares of BAT in exchange for common shares of the Issuer on a one-for-one basis, which transaction served as the Issuer's Qualifying Transaction under the policies of the TSX Venture Exchange (the "**TSXV**").

Further detailed disclosure is contained in the Issuer's filing statement, which is available under the Issuer's profile on SEDAR at www.sedar.com. The acquisition closed on May 24, 2013 and all of the Shares were deposited into escrow pursuant to the terms of the TSXV form 5D *Value Securities Escrow Agreement* (the "**Escrow Agreement**"). At open market on Wednesday, May 28, 2013, the Issuer was classified as a Tier 2 "Biotechnology" company pursuant to the policies of the TSXV, and its common shares commenced trading in the name of "bioMmune Technologies Inc." under the symbol "IMU".

- (c) *The designation and number or principal amount of securities and the offeror's securityholding percentage in the class of securities immediately after the transaction or occurrence giving rise to the obligation to file the news release.*

Prior to the Qualifying Transaction, the Offeror held 575,000 common shares and 175,000 incentive stock options of the Issuer, representing approximately 8.21% of the Issuer's issued and outstanding common shares on a non-diluted basis.

As a result of the foregoing acquisition, the Offeror owns a total of 1,900,000 common shares and 175,000 incentive stock options of the Issuer, and exercises control and direction over an aggregate of 1,325,000 common shares of the Issuer, collectively representing 14.7% of the issued and outstanding common shares of the Issuer on a non-diluted basis. If the Offeror was to exercise all of his options, he would then hold 14.93% of the issued and outstanding common shares of the Issuer, assuming no other options, warrants or convertible securities of the Issuer are exercised or converted and no other shares are otherwise issued by the Issuer.

(d) *The designation and number or principal amount of securities and percentage of outstanding securities of the class of securities referred to in paragraph 3 over which:*

(i) *the offeror, either alone or together with any joint actors, has ownership and control:*

Refer to items (b) and (c) above.

(ii) *the offeror, either alone or together with any joint actors, has ownership but control is held by other persons or companies other than the offeror or any joint actor:*

Not applicable.

(iii) *the offeror, either alone or together with any joint actors, has exclusive or shares control but does not have ownership:*

Not applicable.

(e) *Market where the transaction or occurrence took place.*

N/A. The Shares were acquired pursuant to the terms of the Share Exchange Agreement.

(e1) *The value, in Canadian dollars, of any consideration offered per security if the offeror acquired ownership of a security in the transaction or occurrence giving rise to the obligation to file a news release.*

The Offeror acquired the Shares pursuant to the terms of the Shares Exchange Agreement at a deemed price of \$0.15 per Share.

(f) *The purpose of the offeror and any joint actors in effecting the transaction or occurrence that gave rise to the news release, including any future intention to acquire ownership of, or control over, additional securities of the reporting issuer.*

The Shares were acquired by the Offeror in connection with completion of the Issuer's Qualifying Transaction under the policies of the TSXV, as previously described in Items (b) and (c) above. The Offeror intends to evaluate these security holdings and to increase or decrease the investment as circumstances warrant.

- (g) *The general nature and the material terms of any agreement, other than lending arrangements, with respect to securities of the reporting issuer entered into by the offeror, or any joint actor, and the issuer of the securities or any other entity in connection with the transaction or occurrence giving rise to the news release, including agreements with respect to the acquisition, holding, disposition or voting of any of the securities:*

In connection with completion of the Issuer's Qualifying Transaction, as previously described in Item (b) above, the Offeror entered into a Value Securities Escrow Agreement dated for reference May 22, 2013 among the Issuer, Computershare Investor Services Inc. and certain other security holders, pursuant to which 1,325,000 common shares owned by the Offeror are subject and 1,325,000 common shares over which the Offeror exercises control or direction are subject.

- (h) *The names of any joint actors in connection with the disclosure required by this report:*

Not applicable.

- (i) *In the case of a transaction or occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, the nature and value of the consideration paid by the offeror.*

Refer to items (b) and (c) above.

- (j) *If applicable, a description of any change in any material fact set out in a previous report by the entity under the early warning requirements or Part 4 in respect of the reporting issuer's securities.*

Not applicable.

- (k) *If applicable, a description of the exemption from securities legislation being relied on by the offeror and the facts supporting that reliance.*

Refer to items (b) and (c) above.

Dated the 5th day of June, 2013

"Rob Hutchison"

Rob Hutchison